Add Idarucizumab To Your DOAC Reversal Protocol for Dabigatran
December 2015
Idarucizumab (eye-DAIR-yoo-siz-ooh-mab, Praxbind) will be the first reversal agent for ONE of the direct oral anticoagulants (DOACs).
It's an IV monoclonal antibody fragment that binds to the thrombin inhibitor, dabigatran (Pradaxa), to reverse anticoagulation.
But idarucizumab won't work for factor Xa inhibitors...rivaroxaban (Xarelto), apixaban (Eliquis), or edoxaban (Savaysa)...or other direct thrombin inhibitors like argatroban.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote